News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
US FDA Says Data Inconclusive on Sanofi-Aventis (France) Insulin Risks
January 13, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - U.S. regulators are continuing to probe whether a Sanofi-Aventis diabetes treatment raises cancer risk after determining that data from four studies was inconclusive.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Food and Drug Administration (FDA)
Sanofi (France)
MORE ON THIS TOPIC
Neuroscience
Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data
December 8, 2025
·
2 min read
·
Tristan Manalac
In partnership with PII
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing
December 8, 2025
·
5 min read
·
Jennifer Smith-Parker
Neuroscience
Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA
December 5, 2025
·
2 min read
·
Tristan Manalac
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
·
2 min read
·
Heather McKenzie
